SRXN1 and protein sulfinylation in drug-induced acute liver failure
Official title: Oxidoreductase Sulfiredoxin 1 (SRXN1) and Protein Sulfinylation in Drug-Induced Acute Liver Failure
Funded at University of Pittsburgh at Pittsburgh · NIH-11443985 · Data updated 2026-11-12
A study in people and models aims to understand how a liver toxin (acetaminophen) causes liver failure by oxidative stress and how SRXN1-related processes might help prevent or treat it.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project start | September 1, 2026 |
| Project end | April 30, 2030 |
| Funding year | 2026 |
| Award (this year) | $597,656 |
| NIH project number | 1R01DK145468-01A1 |
| Project ID | NIH-11443985 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are individuals with acetaminophen overdose or patients with acute liver injury of suspected APAP etiology, who could contribute samples or participate in related future studies.
✕Less likely to help
Patients without acetaminophen exposure or non-liver-related conditions may not benefit directly from this research.
What this research studies
This project explores how SRXN1 and protein sulfinylation respond to acetaminophen overdose in the liver, a leading cause of acute liver failure. Researchers will use hepatocytes and animal models to examine how SRXN1 protects liver cells and what happens when it is inhibited or deleted. The work builds on evidence that liver sulfinylation increases after overdose and that hepatocytes are a key source of SRXN1. Findings could point to new strategies to reduce liver injury from overdose and improve treatment options.
Why it matters
Potential benefit: If successful, the research could reveal new targets to prevent or lessen acetaminophen-induced liver injury.
How similar studies have gone: Preliminary data show increased liver sulfinylation after APAP overdose and protective roles for SRXN1 in mice, suggesting a credible path forward.
Where this research is happening
-
University of Pittsburgh at Pittsburgh
Pittsburgh, United States Active
Researchers
- Principal investigator: Xie, Wen — University of Pittsburgh at Pittsburgh
- Study coordinator: Xie, Wen
Related research
Other NIH-funded projects on the same topics.
-
Understanding how CD8 T cells and liver macrophages interact to cause pediatric acute liver failure
A mentoring-based research effort aims to understand how immune cells in the liver contribute to severe liver failure in children.
-
Intestine-targeted LXR therapy to protect the liver in short gut syndrome
This project will try an intestine-only drug that activates LXR to help children with short gut syndrome avoid liver damage.
-
Pediatric Acute Liver Failure: Quieting the Immune System to Help Young Patients
This grant tests immune-suppressing therapies to help children with acute liver failure by calming an overactive immune response.
-
Investigating how a protein affects liver failure during sepsis
This study is looking at how infections can suddenly worsen liver problems in people who already have liver issues, using a special mouse model to explore how certain proteins affect liver health, with the hope of finding better treatments for those affected.
-
Investigating treatments for children with severe liver failure caused by immune responses
This study is looking at new treatments for kids with Pediatric Acute Liver Failure, a serious condition where the liver stops working properly, to see if certain medications can help calm down the immune system and heal the liver, potentially avoiding the need for a liver transplant.
-
Investigating how energy production in mitochondria affects liver health
This study is looking at how problems with energy production in liver cells might affect conditions like nonalcoholic fatty liver disease and liver failure, using a special mouse model to help find new ways to treat these liver issues.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.